Fraudulent Claim Gets The Triple Whammy
Client Alert | less than 1 min read | 03.03.09
In Daewoo Eng'g and Constr. Co. v. U.S. (Fed. Cir. Feb. 20, 2009), the Federal Circuit affirmed the CFC's findings that the contractor had submitted a $64 million claim involving approximately $50 million based on material misrepresentations that amounted to a fraud. From this, the contractor received the triple whammy of forfeiting its entire claim under the CDA, being penalized $50 million under the CDA, and being fined $10,000 under the FCA.
Insights
Client Alert | 2 min read | 09.18.25
On September 9, 2025, the U.S. Department of Health and Human Services (HHS) and the Food and Drug Administration (HHS) issued a news release announcing an “aggressive[]” “crackdown” on direct-to-consumer pharmaceutical advertising. This release came on the heels of a Presidential Memorandum President Trump issued the same day directing HHS to “ensure transparency and accuracy in direct-to-consumer prescription drug advertisements,” and the FDA to “take action to enforce legal requirements that advertisements for prescription drugs be truthful and not misleading.”
Client Alert | 3 min read | 09.17.25
Client Alert | 4 min read | 09.17.25
Client Alert | 5 min read | 09.16.25
Bucking the Odds: Why Technology Companies Should Embrace Software Patents Today
